journal article·2021-05Open access

Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump

Linda Waldherr, Maria Seitanidou, Marie Jakešová, Verena Handl, Sophie Honeder, Marta Nowakowska, Tamara Tomin, Meysam Karami Rad, Tony Schmidt, Joachim Distl, Ruth Birner‐Gruenberger, Gord von Campe, Ute Schäfer, Magnus Berggren, Beate Rinner, Martin Asslaber, Nassim Ghaffari‐Tabrizi‐Wizsy, Silke Patz, Daniel T. Simon, Rainer Schindl

Advanced Materials Technologies· Volume 6· Issue 5

Abstract

Abstract Successful treatment of glioblastoma multiforme (GBM), the most lethal tumor of the brain, is presently hampered by (i) the limits of safe surgical resection and (ii) “shielding” of residual tumor cells from promising chemotherapeutic drugs such as Gemcitabine (Gem) by the blood brain barrier (BBB). Here, the vastly greater GBM cell‐killing potency of Gem compared to the gold standard temozolomide is confirmed, moreover, it shows neuronal cells to be at least 104‐fold less sensitive to Gem than GBM cells. The study also demonstrates the potential of an electronically‐driven organic ion pump (“GemIP”) to achieve controlled, targeted Gem delivery to GBM cells. Thus, GemIP‐mediated Gem delivery is confirmed to be temporally and electrically controllable with pmol min−1 precision and electric addressing is linked to the efficient killing of GBM cell monolayers. Most strikingly, GemIP‐mediated GEM delivery leads to the overt disintegration of targeted GBM tumor spheroids. Electrically‐driven chemotherapy, here exemplified, has the potential to radically improve the efficacy of GBM adjuvant chemotherapy by enabling exquisitely‐targeted and controllable delivery of drugs irrespective of whether these can cross the BBB.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advanced Memory and Neural Computing · Advanced biosensing and bioanalysis techniques · Covalent Organic Framework Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Gottfried Schatz Research Center – Biophysics Medical University of Graz Graz 8010 Austria

Laboratory of Organic Electronics Department of Science and Technology Linköping University Norrköping 60174 Sweden

Department of Neurosurgery Medical University of Graz Graz 8010 Austria

Diagnostic and Research Institute of Pathology Medical University of Graz Graz 8010 Austria

Institute of Chemical Technologies and Analytics Technische Universität Wien Vienna 1060 Austria

Division of Biomedical Research Medical University of Graz Graz 8036 Austria

Otto Loewi Research Center – Immunology and Pathophysiology Medical University of Graz Graz 8010 Austria

Funding

Austrian Science Fund · Knut och Alice Wallenbergs Stiftelse

References (52)

Show source-provided references
1. Goldbrunner R. · Dtsch Arztebl Int. · 2018 · 115 · 356
2. 10.1188/16.CJON.S1.2-810.1188/16.CJON.S1.2-8 ↗
3. 10.1056/NEJMoa04333010.1056/NEJMoa043330 ↗
4. 10.1007/978-3-319-56820-1_110.1007/978-3-319-56820-1_1 ↗
5. 10.1016/j.gendis.2016.04.00710.1016/j.gendis.2016.04.007 ↗
6. 10.1007/s11940-018-0489-210.1007/s11940-018-0489-2 ↗
7. 10.1016/S0140-6736(95)90755-610.1016/S0140-6736(95)90755-6 ↗
8. 10.15586/codon.glioblastoma.2017.ch810.15586/codon.glioblastoma.2017.ch8 ↗
9. Bota D. A. · Ther. Clin. Risk Manage. · 2007 · 3 · 707
10. 10.1586/ern.09.9910.1586/ern.09.99 ↗
11. 10.1185/0300799080250818010.1185/03007990802508180 ↗
12. 10.1586/14737140.2013.84009010.1586/14737140.2013.840090 ↗
13. 10.1007/s00701-006-1097-610.1007/s00701-006-1097-6 ↗
14. 10.1186/s12957-016-0975-510.1186/s12957-016-0975-5 ↗
15. 10.1155/2019/934279610.1155/2019/9342796 ↗
16. 10.1002/admt.20170036010.1002/admt.201700360 ↗
17. 10.1126/sciadv.aau129110.1126/sciadv.aau1291 ↗
18. 10.1021/acs.jpcb.7b0521810.1021/acs.jpcb.7b05218 ↗
19. 10.1126/sciadv.150003910.1126/sciadv.1500039 ↗
20. 10.1038/s41528-019-0060-610.1038/s41528-019-0060-6 ↗
21. 10.1073/pnas.161775811410.1073/pnas.1617758114 ↗
22. 10.1002/smll.20190218910.1002/smll.201902189 ↗
23. 10.1002/adhm.20190081310.1002/adhm.201900813 ↗
24. 10.2165/00003495-199754030-0000910.2165/00003495-199754030-00009 ↗
25. 10.3748/wjg.v12.i10.159710.3748/wjg.v12.i10.1597 ↗
26. 10.1007/s10434-999-0279-x10.1007/s10434-999-0279-x ↗
27. Huang P. · Semin. Oncol. · 1995 · 22 · 19
28. Doyle T. H. · Clin. Cancer Res. · 2001 · 7 · 226
29. Fehlauer F. · Oncol. Rep. · 2006 · 15 · 97
30. Lawrence T. S. · Semin. Oncol. · 1997 · 24 · S7
31. 10.1016/S0305-7372(05)80006-410.1016/S0305-7372(05)80006-4 ↗
32. 10.1111/j.1445-5994.1999.tb00795.x10.1111/j.1445-5994.1999.tb00795.x ↗
33. 10.1021/acsami.7b0594910.1021/acsami.7b05949 ↗
34. Vanysek P. · CRC Hand. Chem. Phys. · 2000 · 83 · 76
35. 10.1021/jp303264410.1021/jp3032644 ↗
36. 10.1371/journal.pgen.100083210.1371/journal.pgen.1000832 ↗
37. Li H. · Turk. Neurosurg. · 2017 · 27 · 894
38. 10.1016/S0014-2999(98)00883-810.1016/S0014-2999(98)00883-8 ↗
39. 10.1016/S1040-8428(00)00085-810.1016/S1040-8428(00)00085-8 ↗
40. 10.1016/j.jbiotec.2010.01.01210.1016/j.jbiotec.2010.01.012 ↗
41. Koledova Z. · 2017 · 110.1007/978-1-4939-7021-6 ↗
42. 10.1371/journal.pone.012331210.1371/journal.pone.0123312 ↗
43. 10.1021/acs.chemrev.6b0014610.1021/acs.chemrev.6b00146 ↗
44. 10.1093/neuonc/nov02910.1093/neuonc/nov029 ↗
45. 10.3171/jns.2003.99.5.089310.3171/jns.2003.99.5.0893 ↗
46. 10.3171/jns.2007.106.2.35110.3171/jns.2007.106.2.351 ↗
47. 10.1126/scitranslmed.300995110.1126/scitranslmed.3009951 ↗
48. 10.1038/nmat249410.1038/nmat2494 ↗
49. 10.3389/fneur.2019.0041010.3389/fneur.2019.00410 ↗
50. 10.1136/jnnp.71.2.21510.1136/jnnp.71.2.215 ↗
51. 10.3389/fchem.2019.0048410.3389/fchem.2019.00484 ↗
52. 10.1039/C9LC00038K10.1039/C9LC00038K ↗